# A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)

> **NCT02493751** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 55 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Avelumab (MSB0010718C)
- **DRUG:** Axitinib (AG-013736)

## Key facts

- **NCT ID:** NCT02493751
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-26
- **Primary completion:** 2018-04-03
- **Final completion:** 2021-03-04
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493751, "A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02493751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*